Medical Radiology and Radiation Safety. 2026. Vol. 71. № 6

DOI:10.33266/1024-6177-2026-71-6-127-134

K.O. Avrov1, S.V. Shatik1, O.A. Shashkova1, A.A. Pinevich1, L.A. Terekhina1, I.V. Gryazeva1, V.V. Zaitsev1, A.A. Stanzhevskiy1, M.P. Samoylovich1, 2

EFFECT OF THE COMPOSITION AND ROUTE OF ADMINISTRATION OF NANOBODY-BASED RADIOCONJUGATES ON RADIOACTIVITY ACCUMULATION IN MOUSE KIDNEYS

1 A.M. Granov Russian Research Center of Radiology and Surgical Technologies, St. Peterburg, Russia

2 Saint Petersburg State University, St. Peterburg, Russia

Contact person: Kirill Olegovich Avrov, e-mail: This email address is being protected from spambots. You need JavaScript enabled to view it.

ABSTRACT

Purpose: This study investigated the level of accumulation of based on nanoantibodies radioconjugates in the kidneys of mice, depending on the composition and the route of administration. 

Material and methods: Radioconjugates were prepared using nanoantibodies specific to the biomarkers PD-L1, HER2/neu, and VEGFR2, along with the chelating agents p-SCN-Bn_DOTA or the ethyl squarate derivative of deferoxamine. Experiments were performed using  F1 (DBA/2×BALB/c) mice. 100 μL of the radioconjugate solutions were injected into the retroorbital venous sinus, tail vein, or subcutaneously. A study of the radioconjugate’s biodistribution in experimental animals was performed 4 or 24 hours after administration of antibodies conjugated with 177Lu radionuclide and 0.5, 1, 1.5, or 2 hours after administration of antibodies labeled with the 68Ga radionuclide. Direct organ and tissue dosimetry was used to measure the biodistribution of the radioconjugates.

Results: It was found that radioconjugates containing the same radionuclides and the same chelator (DOTA), but manufactured on the basis of different nanoantibodies, accumulate in the kidneys differently after administration. Thus, it was established that 30 minutes after the administration of [68Ga]Ga-VHH HER2/neu, the radioactivity of the kidneys was twice lower than after the administration of [68Ga]Ga-VHH PD-L1. 24 hours after the administration of (177Lu)Lu-VHH VEGFR2, such radioactivity was also twice lower than after the administration of [177Lu]Lu-VHH PD-L1. Moreover, for these pairs of radioconjugates, the radioactivity of the urine was also lower after the administration of [68Ga]Ga-VHH HER2/neu or [177Lu]Lu-VHH VEGFR2. Replacing DFO with DOTA as the chelating group for [68Ga]Ga-VHH HER2/neu significantly reduced kidney radioactivity at 1 and 2 hours after administration of this radioconjugate. Kidney radioactivity was also shown to depend on the route of administration of the radioconjugates. Four hours after subcutaneous administration of [177Lu]Lu-VHH PD-L1, the relative kidney radioactivity was approximately 3 times lower than after administration of the radioconjugate into the tail vein, while 1 hour after administration of [68Ga]Ga-VHH PD-L1, effect of different administration was twofold. Moreover, after [177Lu]Lu-VHH PD-L1 administration into the tail vein, its biodistribution in other organs and tissues was the same as after subcutaneous or retroorbital sinus administration. It was shown that 1 minute after subcutaneous administration of (68Ga)Ga-VHH PD-L1, significantly less radioconjugate entered the bloodstream than after its administration into the tail vein. Based on the data obtained, it was suggested that the accumulation of radioactivity in the kidneys could be reduced by increasing the duration of administration of the radioconjugate into the bloodstream.

Conclusion: It was shown that radioconjugate accumulation in the kidneys depends on the nanoantibodies and chelating groups used for their synthesis, as well as on the method of radioconjugate administration. The obtained data open up new ways to reduce radiation exposure to the kidneys during targeted diagnostics or therapy.

 

Keywords: radioconjugates, radionuclides, nanoantibodies, chelators, kidneys, bloodflow, mice

For citation: Avrov KO, Shatik SV, Shashkova OA, Pinevich AA, Terekhina LA, Gryazeva IV, Zaitsev VV, Stanzhevskiy AA, Samoylovich MP. Effect of the Composition and Route of Administration of Nanobody-Based Radioconjugates on Radioactivity Accumulation in Mouse Kidneys. Medical Radiology and Radiation Safety. 2026;71(6):127–134. DOI:10.33266/1024-6177-2026-71-6-127-134

 

References

1. Freise A.C., Wu A.M. In Vivo Imaging with Antibodies and Engineered Fragments. Mol. Immunol. 2015;67;2 Pt A:142–152. Doi: 10.1016/j.molimm.2015.04.001.

2. Chigoho D.M., Bridoux J., Hernot S. Reducing the Renal Retention of low to Moderate-Molecular-Weight Radiopharmaceuticals. Curr. Opin. Chem. Bbiol. 2021;63:219–228. Doi: 10.1016/j.cbpa.2021.06.008.

3. Авров К.О., Шатик С.В., Шашкова О.А., Пиневич А.А., Терехина Л.А., Грязева И.В., Зайцев В.В., Берлина М.А., Станжевский А.А., Самойлович М.П. Оценка функциональной пригодности радиоиммуноконъюгатов наноантител против PD-L1 и HER2/NEU для тераностики опухолей // Современные технологии в медицине. 2026. Т.18. №2. С. 24–38 [Avrov K.O., Shatik S.V., Shashkova O.A., Pinevich A.A., Terekhina L.A., Gryazeva I.V., Zaytsev V.V., Berlina M.A., Stanzhevskiy A.A., Samoylovich M.P. Evaluation of the Functional Suitability of Radioimmunoconjugates of Nanoantibodies against PD-L1 and HER2/NEU for Tumor Theranostics. Sovremennyye Tekhnologii v Meditsine = Modern Technologies in Medicine. 2026;18;2:24–38 (In Russ.)].

4. Jin B.K., Odongo S., Radwanska M., Magez S. NANOBODIES®: A Review of Diagnostic and Therapeutic Applications. Int. J. Mol. Sci. 2023;24;6:5994. Doi: 10.3390/ijms24065994.

5. Bridoux J., Broos K., Lecocq Q., Debie P., Martin C., Ballet S., Raes G., Neyt S., Vanhove C., Breckpot K., Devoogdt N., Caveliers V., Keyaerts M., Xavie C.  Anti-Human PD-L1 Nanobody for Immuno-PET Imaging: Validation of a Conjugation Strategy for Clinical Translation. Biomolecules 2020;10;10:1388. Doi: 10.3390/biom10101388.

6. Zhao L., Gong J., Liao S., Huang W., Zhao J., Xing Y. Preclinical Evaluation and Preliminary Clinical Study of 68Ga-NODAGA-NM-01 for PET Imaging of PD-L1 Expression. Cancer Imaging 2025;25;1:6. Doi: 10.1186/s40644-025-00826-8.

7. Gao H., Wu Y., Shi J., Zhang X., Liu T., Hu B., Jia B., Wan Y., Liu Z., Wang F. Nuclear Imaging-Guided PD-L1 Blockade Therapy Increases Effectiveness of Cancer Immunotherapy. J. Iimmunother. Cancer. 2020;8;2:e001156. Doi: 10.1136/jitc-2020-001156.

8. D’Huyvetter M., Vincke C., Xavier C., Aerts A., Impens N., Baatout S., De Raeve H., Muyldermans S., Caveliers V., Devoogdt N., Lahoutte T. Targeted Radionuclide Therapy with A 177Lu-Labeled Anti-HER2 Nanobody. Theranostics. 2014;4;7:708-720. Doi: 10.7150/thno.8156. 

9. Behr T.M., Becker W.S., Sharkey R.M., Juweid M.E., Dunn R.M., Bair H.J., Wolf F.G., Goldenberg D.M. Reduction of Renal Uptake of Monoclonal Antibody Fragments by Amino Acid Infusion. J. Nucl. Med. 1996;37;5:829-833. PMID: 8985154.

10. Авров К.О., Шатик С.В., Самойлович М.П. Способы уменьшения накопления радиоактивности в почках при таргетной терапии с использованием малых молекул, пептидов и фрагментов антител // Сибирский онкологический журнал. 2024. Т.3. №4. С. 162-171 [Avrov K.O., Shatik S.V., Samoylovich M.P. Methods for Reducing the Accumulation of Radioactivity in the Kidneys during Targeted Therapy using Small Molecules, Peptides and Antibody Fragments. Sibirskiy Onkologicheskiy Zhurnal = Siberian Journal of Oncology. 2024;3;4:162-171 (In Russ.)]. Doi: 10.21294/1814-4861-2024-23-4-162-171.

11. Kuo H.T., Pan J., Zhang Z., Lau J., Merkens H., Hang C., Colpo N., Lin K.S., Bénard F. Effects of Linker Modification on Tumor-to-Kidney Contrast of 68Ga-Labeled PSMA-Targeted Imaging Probes. Mol. Pharm. 2018;15:3502–3511. Doi: 10.1021/acs.molpharmaceut.8b00499.

12. Baranski A.C., Schäfer M, Bauder-Wüst U/, Wacker A/, Schmidt J., Liolios C., Mier W., Haberkorn U., Eisenhut M., Kopka K., Eder M. Improving the Imaging Contrast of 68Ga-PSMA-11 by Targeted Linker Design: Charged Spacer Moieties Enhance the Pharmacokinetic Properties. Bioconjug. Chem. 2017;28;9:2485-2492. Doi: 10.1021/acs.bioconjchem.7b00458.

13. Flook A.M., Yang J., Miao Y. Substitution of the Lys Linker with the β-Ala Linker Dramatically Decreased the Renal Uptake of 99mTc-labeled Arg-X-Asp-Conjugated and X-Ala-Asp-Conjugated α-Melanocyte Stimulating Hormone Peptides. J. Med. Chem. 2014;57;21:9010-8. Doi: 10.1021/jm501114v.

14. Hofström C., Altai M., Honarvar H., Strand J., Malmberg J., Hosseinimehr S.J., Orlova A., Gräslund T., Tolmachev V. HAHAHA, HEHEHE, HIHIHI, or HKHKHK: Influence of Position and Composition of Histidine Containing Tags on Biodistribution of [(99m)Tc(CO)3](+)-Labeled Affibody Molecules. J. Med. Chem. 2013;56;12:4966-74. Doi: 10.1021/jm400218y.

15. Guo H., Yang J., Gallazzi F., Prossnitz E.R., Sklar L.A., Miao Y. Effect of DOTA Position on Melanoma Targeting and Pharmacokinetic Properties of 111In-Labeled Lactam Bridge-Cyclized Alpha-Melanocyte Stimulating Hormone Peptide. Bioconjug. Chem. 2009;20;11:2162-8. Doi: 10.1021/bc9003475.

16. Mitran B., Thisgaard H., Rinne S., Dam J.H., Azami F., Tolmachev V., Orlova A., Rosenström U. Selection of an Optimal Macrocyclic Chelator Improves the Imaging of Prostate Cancer using Cobalt-Labeled GRPR Antagonist RM26. Sci. Rep. 2019;9;1:17086. Doi: 10.1038/s41598-019-52914-y. 

17. George S., Bourlon M.T., Overman M.J., Dixon M., Shelley K., Markus K. J., Kewley R. M., Pope S. I., Albigès, L. Systematic Literature Review of Intravenous Versus Subcutaneous Administration of Oncology Therapies: a Clinical, Economic and Patient Perspective. Cancer Treat. Rev. 2025;139:102974. Doi: 10.1016/j.ctrv.2025.102974.

18. Stoner K.L., Harder H., Fallowfield L.J., Jenkins V.A. Intravenous Versus Subcutaneous drug Administration. Which do Patients Prefer? A Systematic Review. Patient. 2014 Jul 12;8;2:145-153. Doi: 10.1007/s40271-014-0075-y.

19. Ren Q.I., Baty C.J., Kashlan O.B., Eisz O.A.  Distinct Functions of Megalin and Cubilin Receptors in Recovery of Normal and Nephrotic Levels of Filtered Albumin. Am. J. Physiol. Renal Physiol. 2020;318;5:F1284–F1294. Doi: 10.1152/ajprenal.00030.2020.

20. Vegt E., de Jong M., Wetzels J.F., Masereeuw R., Melis M., Oyen W.J., Gotthardt M., Boerman O.C. Renal Toxicity of Radiolabeled Peptides and Antibody Fragments: Mechanisms, Impact on Radionuclide Therapy, and Strategies for Prevention. J. Nucl. Med. 2010;51;7:1049-58. Doi: 10.2967/jnumed.110.075101.

 

 PDF (RUS) Full-text article (in Russian)

 

Conflict of interest.The authors declare no conflict of interest.

Financing. This work was supported by a state assignment from the Russian Ministry of Health.

Contribution. K.O. Avrov, O.A. Shashkova and M.P. Samoylovich designed the study and conducted animal experiments. S.V. Shatik and V.V. Zaytsev synthesized the radioconjugates. A.A. Pinevich, L.A. Terekhova and I.V. Gryazeva conducted animal experiments.

Article received: 20.06.2026. Accepted for publication: 25.07.2026